Related references
Note: Only part of the references are listed.Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Louisa R. Hoes et al.
CLINICAL CANCER RESEARCH (2022)
Delivering precision oncology to patients with cancer
Joaquin Mateo et al.
NATURE MEDICINE (2022)
Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe
A. Lamarca et al.
ANNALS OF ONCOLOGY (2022)
A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial
Yohei Chiba et al.
BMC CANCER (2022)
Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results.
Yohann Loriot et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
A. Jahn et al.
ANNALS OF ONCOLOGY (2022)
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)
A. Bayle et al.
ANNALS OF ONCOLOGY (2022)
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
A. Haslam et al.
ANNALS OF ONCOLOGY (2021)
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
C. E. Heilig et al.
ESMO OPEN (2021)
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
Mihaela Aldea et al.
CANCER DISCOVERY (2021)
TCF-001 TRACK (Target Rare Cancer Knowledge): A national patient-centric precision oncology trial for rare cancers.
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN
Marie Morfouace et al.
ESMO OPEN (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
O. Tredan et al.
ANNALS OF ONCOLOGY (2019)
Phase I trials as valid therapeutic options for patients with cancer
Jacob J. Adashek et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
K. Fizazi et al.
ANNALS OF ONCOLOGY (2019)
2037PA challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience
C Pauli et al.
ANNALS OF ONCOLOGY (2019)
Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers
Roman Groisberg et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
Loic Verlingue et al.
EUROPEAN JOURNAL OF CANCER (2017)
Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study
Gemma Gatta et al.
LANCET ONCOLOGY (2017)
Whole-genome landscape of pancreatic neuroendocrine tumours
Aldo Scarpa et al.
NATURE (2017)
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
Steven Lemery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Christophe Massard et al.
CANCER DISCOVERY (2017)
The Burden of Rare Cancers in the United States
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Determinants of patient screen failures in Phase 1 clinical trials
Alexandra Mckane et al.
INVESTIGATIONAL NEW DRUGS (2013)
Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors
David Olmos et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Rare cancers are not so rare: The rare cancer burden in Europe
Gemma Gatta et al.
EUROPEAN JOURNAL OF CANCER (2011)
The Occurrence of Rare Cancers in US Adults, 1995-2004
Robert T. Greenlee et al.
PUBLIC HEALTH REPORTS (2010)